LEGN Quote, Financials, Valuation and Earnings

Agenus has a net margin of 14.09% compared to Legend Biotech's net margin of -170.88%. Legend Biotech's return on equity of -15.44% beat Agenus's return on equity of --.

Legend Biotech has a consensus price target of $77.99, signalling upside risk potential of 143.42%. On the other hand Agenus has an analysts' consensus of $6.00 which suggests that it could grow by 97.37%. Given that Legend Biotech has higher upside potential than Agenus, analysts believe Legend Biotech is more attractive than Agenus.

Legend Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Agenus has a beta of 1.476, suggesting its more volatile than the S&P 500 by 47.645%.

Legend Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech pays -- of its earnings as a dividend. Agenus pays out -- of its earnings as a dividend.

Legend Biotech quarterly revenues are $186.5M, which are larger than Agenus quarterly revenues of $26.8M. Legend Biotech's net income of $26.3M is higher than Agenus's net income of -$45.9M. Notably, Legend Biotech's price-to-earnings ratio is -- while Agenus's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech is 9.34x versus 0.49x for Agenus. Usually stocks with elevated PS ratios are considered overvalued.

Alnylam Pharmaceuticals has a net margin of 14.09% compared to Legend Biotech's net margin of -9.67%. Legend Biotech's return on equity of -15.44% beat Alnylam Pharmaceuticals's return on equity of --.

Legend Biotech has a consensus price target of $77.99, signalling upside risk potential of 143.42%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $320.56 which suggests that it could grow by 24.08%. Given that Legend Biotech has higher upside potential than Alnylam Pharmaceuticals, analysts believe Legend Biotech is more attractive than Alnylam Pharmaceuticals.

Legend Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.169, suggesting its less volatile than the S&P 500 by 83.104%.

Legend Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

Legend Biotech quarterly revenues are $186.5M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. Legend Biotech's net income of $26.3M is higher than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, Legend Biotech's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech is 9.34x versus 14.14x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Biomarin Pharmaceutical has a net margin of 14.09% compared to Legend Biotech's net margin of 24.92%. Legend Biotech's return on equity of -15.44% beat Biomarin Pharmaceutical's return on equity of 9.62%.

Legend Biotech has a consensus price target of $77.99, signalling upside risk potential of 143.42%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.02 which suggests that it could grow by 60.51%. Given that Legend Biotech has higher upside potential than Biomarin Pharmaceutical, analysts believe Legend Biotech is more attractive than Biomarin Pharmaceutical.

Legend Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.268, suggesting its less volatile than the S&P 500 by 73.157%.

Legend Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Legend Biotech quarterly revenues are $186.5M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.1M. Legend Biotech's net income of $26.3M is lower than Biomarin Pharmaceutical's net income of $185.7M. Notably, Legend Biotech's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 22.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech is 9.34x versus 4.01x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 14.09% compared to Legend Biotech's net margin of 26.7%. Legend Biotech's return on equity of -15.44% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Legend Biotech has a consensus price target of $77.99, signalling upside risk potential of 143.42%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $800.13 which suggests that it could grow by 46.1%. Given that Legend Biotech has higher upside potential than Regeneron Pharmaceuticals, analysts believe Legend Biotech is more attractive than Regeneron Pharmaceuticals.

Legend Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Legend Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.16% to investors and pays a quarterly dividend of $0.88 per share. Legend Biotech pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Legend Biotech quarterly revenues are $186.5M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Legend Biotech's net income of $26.3M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Legend Biotech's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech is 9.34x versus 4.44x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.